Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics Read More > July 1, 2003
Activities of extract and constituents of Banisteriopsis caapi relevant to parkinsonism Read More > June 14, 2003
Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Read More > March 1, 2003
Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia Read More > February 1, 2003
Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binocular depth inversion in man Read More > January 1, 2003
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up Read More > June 24, 2002
Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers Read More > June 24, 2002
Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach. Read More > January 1, 2002
No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study Read More > February 1, 2001
